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The inhibition of several chemokine/chemokine receptors
has been shown to reduce progressive renal interstitial
fibrosis. In this study, we examined the expression of the
CX3C receptor in human renal biopsies with interstitial
fibrosis and from normal kidneys by real-time polymerase
chain reaction (PCR) and immunohistochemistry. The CX3C
receptor was not only detected in mononuclear, tubular
epithelial, and dendritic cells but also in a-smooth muscle
actin and vimentin-positive interstitial myofibroblasts in
fibrotic kidneys. Real-time PCR indicated a significant
upregulation of CX3C receptor mRNA in fibrotic kidneys
compared with non-fibrotic nephropathies or donor biopsies.
In renal fibroblasts in vitro, hydrogen peroxide increased the
expression of the CX3C receptor, an increase that was
inhibited by N-acetylcysteine and catalase. However, neither
proinflammatory nor profibrotic cytokines resulted in this
upregulation. Stimulation of fibroblasts by CX3C ligand led to
a significant enhancement of migration, which was
abrogated by pre-incubation with a blocking anti-CX3C
receptor antibody. Our studies indicate that renal fibrosis is
associated with the expression of CX3C receptors on human
renal fibroblasts. The expression is induced by reactive
oxygen species suggesting a role of oxidative stress.
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Tubulointerstitial fibrosis is a key component of the final
common pathway in progressive chronic kidney disease and
its extent is closely associated with the loss of renal
function.1–3 The pathogenesis of renal fibrogenesis is complex
and incompletely understood.4
A number of studies have demonstrated that chemokines
are key mediators in various stages of that process.5,6 Chemo-
kines are a family of proteins, which control aspects of cell
migration, activation, proliferation, and adhesion.5,7,8
Furthermore, there is increasing evidence that certain
chemokines do not only play an important role in
amplification and perpetuation of interstitial inflammation,
but also in the complex interactions resulting in fibroblast
proliferation and matrix accumulation.5,9
The sole member of the CX3C chemokine family is
fractalkine (CX3C-L), which binds to the CX3C receptor
(CX3C-R). In the kidney, CX3C-L expression has been
described in glomerular and vascular endothelial cells, on
glomerular and tubular epithelial cells, mesangial cells, and in
stromal tissue including the tubulointerstitial space.7,10–12
CX3C-L expression could be induced by proinflammatory
cytokines, CX3C-L itself, by proteinuria in tubular epithelial
cells and also by the profibrotic cytokines such as platelet-
derived growth factor (PDGF) or basic fibroblastic growth
factor-2 (FGF-2).13–19 CX3C-L exerts strong adhesive proper-
ties on different subsets of mononuclear cells,20–22 prolif-
erative and antiapoptotic activity on epithelial, mesenchymal,
or neuronal cells,7,23,24 upregulates expression of matrix
metalloproteinases, interleukin (IL)-8, or CX3C-L itself,
10,23
respectively, suggesting auto/paracrine properties.7,23 More-
over, the functional significance of CX3C-L in progression of
renal diseases has been demonstrated by inhibition of its
receptor, CX3C-R, in crescentic anti-thy 1.1 nephritis,
25 lupus
nephritis26 as well as ischemia–reperfusion injury.27
CX3C-R is expressed on a number of leukocytes, including
monocytes, T cells, and dendritic cells.20–22,28–30 In contrast to
most chemokine receptors, expression has been demon-
strated in several intrinsic cells including vascular smooth
muscle cells, synovial fibroblasts, or epithelial cells of the
bowel.10,18,23 In normal and inflammatory diseases of the
human kidney, CX3C-R expression was detectable in
infiltrating mononuclear cells, stromal cells, smooth muscle
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cells of preglomerular vessels as well as within the
tubulointerstitial space, though the cellular source of the
latter was not further specified.12,29 The regulation of CX3C-
R expression is largely unknown, although induction by the
profibrotic cytokine transforming growth factor-b (TGF-b)
has been described in microglia cells.31
Studies of the expression of CX3C-R have been confined to
acute inflammatory states of the kidney and the functional
analyses of CX3C-L in regard to invasion of mononuclear
cells. Here, we describe the expression of CX3C-R in
interstitial fibroblasts in fibrotic kidneys and investigated
possible mechanisms of the regulation of CX3C-R.
RESULTS
Expression of CX3C-R in normal and fibrotic human kidneys
The pattern of expression for the CX3C-R is shown in
Figure 1. In normal kidneys, no expression was detectable in
any compartment (Figure 1a), except for three biopsies
in which a mild expression was found within tubular
epithelial cells (Table 1).
Evaluation of fibrotic kidneys demonstrated CX3C-R
positively stained cells within the tubulointerstitium of
medulla and cortex. These cells were found massed around
sclerotic glomeruli (Figure 1b), but also within the
tubulointerstitial space. In serial sections, these cells could
only partially be colabeled by a series of antibody reagents
directed against lymphocytes and monocytes/macrophage
antigens (CD3 and CD68). Counting the number of
positively stained cells per interstitial visual field, the number
of CX3C-R-positive cells exceeded the sum of CD3- and
CD68-expressing cells by the factor 4.6 in fibrotic kidneys
(P¼ 0.001 using paired Wilcoxon test) (Figure 2). Addition-
ally, in tubular epithelial cells, CX3C-R expression was mild
to strong in 70% (17 from 24 biopsies) with a representative
example shown in Figure 1d. Results of semiquantitative
evaluations are summarized in Table 1.
In double immunofluorescence stainings, we found no
constitutional expression of CX3C-R in normal human
kidneys (Figure 3a and d). In fibrotic kidneys, CX3C-R was
found in tubular epithelial cells (Figure 3b). Additionally, we
found a positive double staining for CX3C-R, and the marker
for myofibroblasts, a-smooth muscle actin (Figure 3c) or the
mesenchymal marker vimentin (data not shown), in several
cells within the tubulointerstitial space. Moreover, there was a
cohort of interstitial cells coexpressing the dendritic cell
markers, CD11c and CX3C-R (Figure 3e).
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Figure 1 | Expression of CX3C-R in normal human and fibrotic kidneys after immunohistochemical staining. (a) No CX3C-R was detectable
in any compartment in normal human kidneys. In fibrotic kidneys, (b–d) CX3C-R was detected in infiltrating mononuclear cells (small arrows),
tubular epithxelial cells (arrow heads), and in (b, c) interstitial cells (big arrows). The inset (b) displays the negative control. (d) A strong
expression of CX3C-R is demonstrated in tubular epithial cells (arrow heads). Original magnification  400, inset  100.
Table 1 | Results of CX3C-R expression in normal and fibrotic human kidneys after immunohistochemical staining
Bowman epithelium Tubular epithelial cells Interstitial cells Infiltrates*
Normal kidney Fibrotic kidney Normal kidney Fibrotic kidney Normal kidney Fibrotic kidney Normal kidney Fibrotic kidney
0 8/8 (100%) 22/24 (92%) 5/8 (62.5%) 7/24 (30%) 7/8 (87.5%) 7/24 (30%) — 2/24 (8%)
+ 0/8 (0%) 2/24 (8%) 3/8 (37.5%) 7/24 (30%) 1/8 (12.5%) 11/24 (46%) — 7/24 (30%)
++ 0/8 (0%) 0/24 (0%) 0/8 (0%) 5/24 (20%) 0/8 (0%) 4/24 (17%) — 4/24 (17%)
+++ 0/8 (0%) 0/24 (0%) 0/8 (0%) 5/24 (20%) 0/8 (0%) 2/24 (7%) — 11/24 (45%)
CX3C-R, fractalkine receptor.
Sections were deparaffinized and stained for CX3C-R according to a modified sandwich technique. Tissues were evaluated semiquantitatively (0 to +++).
*No infiltrates were seen in normal human kidneys.
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The total expression of CX3C-R mRNA was robustly
upregulated in biopsies from fibrotic kidneys compared with
cadaveric donor biopsies (control) and non-fibrotic nephro-
pathies (2.1- and 2.2-fold, respectively) by quantitative real-
time polymerase chain reaction (PCR) (P¼ 0.045 comparing
control vs fibrosis, and P¼ 0.045 comparing no fibrosis vs
fibrosis using the t-test to the log-transferred data) (Figure 4).
Even, if one takes into consideration that a decrease in
tubular epithelial cells may favor an increase in expression in
molecules expressed in interstitial cells, this increase remains
robust. There was no correlation found between the mRNA
quotient CX3C-R/glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) and serum creatinine (R2¼ 0.12) and only a
slight correlation with the daily amount of proteinuria
(R2¼ 0.34).
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Figure 2 | Number of CX3C-R, CD3 or CD68 positively stained cells
within a tubulointerstitial visual field in fibrotic kidneys. After
immunohistochemical detection of CX3C-R, CD3, or CD68, positively
stained cells were counted separately in serial sections and the sum
of CD3- and CD68-positively stained cells were compared with the
number of CX3C-R-positive cells. The results show that CX3C-R
positively stained cells (CX3C-Rþ ) exceed the sum of CD3- and
CD68-positively stained cells (SCD3þ /CD68þ ) within
a tubulointerstitial visual field (original magnification  400). Mean
values7s.d. are shown.
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Figure 4 | Tubulointerstitial expression of CX3C-R mRNA in biopsy
material from patients with fibrotic kidneys (fibrosis) examined
with quantitative real-time reverse transcription PCR after tissue
microdissection. Cadaveric kidneys and non-fibrotic primary or
secondary nephropathies served as controls. Results are expressed as
CX3C-R/GAPDH ratio. Mean values7s.d. are shown. *P¼ 0.045
compared with control or to no fibrosis.
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Figure 3 | Immunoflourescence staining of CX3C-R, a-smooth muscle actin and CD11c. Double immunoflourescence staining of CX3C-R
and (a–c) a-smooth muscle actin or (d and e) CX3C-R and CD11c in (a and d) normal kidney, and kidney with a low degree of
(b) tubulointerstitial fibrosis and (c and e) end-stage renal failure. (a and d) In normal kidney, there was a discrete expression of (a) a-smooth
muscle actin and (d) CD11c (both green, small arrows), and no expression of CX3C-R (red). In the kidney with a low degree of
(b) tubulointerstitial fibrosis, we found a de novo expression of CX3C-R (red) within the tubules (arrow head). (c) In end-stage kidneys, we
detected a-smooth muscle actin-positive myofibroblasts (green) within the interstitium (small arrow) and CX3C-R-positive cells (red) within the
tubules (arrow head). Additionally, we found a cohort of interstitial cells who stained positively for both markers (orange, big arrow). Moreover,
we found a co-expression of CD11c and CX3C-R (orange, big arrow) in (e) end-stage kidney. Original magnification  400.
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Human renal fibroblasts express CX3C-R
Constitutive expression of CX3C-R in the human cortical
fibroblast cell lines (Tk173 and Tk188) as well as in primary
fibroblasts Tk461 was demonstrated by immunofluorescence
and reverse-transcription PCR (Figure 5).
Neither proinflammatory nor fibrotic cytokines, but H2O2
induce a CX3C-R upregulation
To examine whether CX3C-R could be upregulated by
proinflammatory or profibrotic cytokines, fetal calf serum
(FCS)-starved Tk173 or Tk188 were treated for 24 h with 10 ng/
ml of either the proinflammatory cytokines, IL-1b, or tumor
necrosis factor-a, or the profibrotic cytokines PDGF, epithelial
growth factor, FGF-2, or TGF-b. Under these conditions, there
were no significant differences in CX3C-R/GAPDH coefficient
in real-time PCR results in every investigated cytokine
stimulated (Figure 6a). Shorter (6 h) or longer (48 h) stimula-
tion did not change the CX3C-R expression level.
Conversely, stimulation with non-toxic doses of the
reactive oxygene species H2O2 (0.1 mM) resulted in strong
upregulation in renal fibroblasts with 8617241% of controls
in Tk173 (Po0.0001 using the Mann–Whitney U-rank test
adjusted for multiple choice comparison) and 10277349.1%
in Tk188 (Po0.0001 also using the adjusted rank test)
fibroblasts with a dose-dependent effect exemplarily demon-
strated in Tk173 (Figure 6b). To further characterize these
results, Tk173 were treated with H2O2 (0.1 mM) in the
presence or absence or N-acetyl-L-cysteine (NAC, 1 mM) and
catalase (600 U/ml) for 24 h. H2O2 upregulated the expres-
sion of CX3C-R, which was completely abrogated by pre-
incubation with the radical scavengers NAC and catalase by
99.4% (Po0.0001 compared with H2O2-stimulated cells
using the adjusted Mann–Whitney U-test). Figure 6c
summarizes the results.
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Figure 5 | Constitutive expression of CX3C-R in human primary
renal fibroblasts (Tk461) as well as in two fibroblast cell lines from
a non-fibrotic (Tk173) and fibrotic kidney (Tk188). In the fibroblast
cell lines, Tk173 and 188, as well in primary renal fibroblasts (Tk461),
CX3C-R expression has been ascertained by immunofluorescence
staining. (a) The expression in Tk461 is exemplarily shown. (b) Negative
control. (c) The constitutive expression of CX3C-R has been detected by
reverse transcription PCR in fibroblast cell lines from a non-fibrotic
(Tk173) and fibrotic (Tk188) kidney.
0
200
400
600
800
1000
1200
1400 Tk173
Tk188
*
*
0
200
400
600
800
1000
1200
co                          0.001                         0.01                        0.1
H2O2 (mM)
m
R
N
A 
CX
3C
-R
/G
AP
DH
*
*
*
0
200
400
600
800
1000
1200
m
R
N
A 
CX
3C
-R
/G
AP
DH
*
**
co IL-1 TNF- PDGF EGF FGF-2 TGF- H2O2
co H2O2 H2O2+NAC+
catalase
NAC+catalase 
Figure 6 | CX3C-R expression in human renal fibroblasts (Tk173
and Tk188) incubated with pro-inflammatory or pro-fibrotic
cytokines as well as with H2O2 in presence and absence of radical
scavengers NAC and catalase. Tk173 and 188 were left untreated
(control) or incubated for 24 h with in vivo relevant concentrations
(10 ng/ml) of IL-1b, tumor necrosis factor-a, PDGF, epithelial growth
factor, FGF-2, TGFb, or 0.1 mM H2O2. CX3C-R expression was detected
by quantitative reverse transcription PCR in comparison with the
house-keeping gene (a) GAPDH. The effects were specific with a
dose-dependent increase in CX3C-R/GAPDH quotient in Tk173, after
incubation with raising doses (b) H2O2. Co-incubation of Tk173 with
0.1 mM H2O2 with the radical scavengers NAC and catalase completely
abrogated the induction of (c) CX3C-R. Mean values7s.d. are shown.
*Po0.05 compared with control and **Po0.05 compared with
positive control H2O2.
602 Kidney International (2007) 72, 599–607
o r i g i n a l a r t i c l e MJ Koziolek et al.: CX3C-R expression in renal fibrosis
CX3C-L enhances migration of human fibroblasts
Since CX3C-L is a potent chemoattractant also for intrinsic
cells,7,32 we investigated chemotactic effects of CX3C-L on
human renal fibroblasts. CX3C-L induced cell motility in a
dose-dependent manner as assessed by migration assay up to
a maximum of 380725% in Tk461, 5947228% in Tk173,
and 7457187% of controls in Tk188 (all n¼ 6, Po0.0001
using the Mann–Whitney U-rank test adjusted for multiple
comparison) under stimulation with 20 ng/ml CX3C-L. Pre-
incubation of fibroblasts with a blocking anti-CX3C-R
antibody resulted in a significant reduction of migrated cells
under a stimulation with 20 ng/ml CX3C-L by a rate of 57.9%
in Tk461, 57.1% in Tk173, and 53.8% in Tk188 (all
Po0.0001 compared to stimulation with 20 ng/ml CX3C-L
using the adjusted rank test). These results are summarized in
Figure 7.
DISCUSSION
In the past, there have been several reports on the role of
chemokines and their receptors in progressive renal failure.
After inhibition of CCL-2/MCP-1, CCL-5/Rantes, CX3C-L or
their corresponding receptors, respectively, a significant
reduction of infiltrating sites and a reduction of irreversible,
chronic tubulointerstitial damages has been achieved in
several models of progressive glomerular and tubulointer-
stitial diseases.5,13,25 The reduction of inflammation is
thought to be the main cause underlying this amelioration.
Recent data suggested additional mechanisms of CX3C-L or
CX3C-R in extrarenal tissues.
7,23,24
We used immunohistochemical detection of CX3C-R,
double immunofluorescence staining for CX3C-R and several
epithelial and mesenchymal markers along with real-time
PCR and, additionally, in vitro analyses for the localization
and quantification of the CX3C-R. The main finding in our
study was that CX3C-R is not only expressed in CD3- and
CD68-positive infiltrating cells but also in resident interstitial
cells with a CD3- and CD68-negative staining pattern, and in
tubular epithelial cells in advanced stages of renal disease.
Segerer et al.29 described CX3C-R-positive cells in the two
most common groups of infiltrating cells, T cells and
monocytes/macrophages, in human inflammatory kidney
diseases or renal allograft rejection, although the authors
could not exclude an expression in stromal cells. Another
CX3C-R-positive interstitial cell type are dendritic cells,
which have been shown to form a heterogenous pervasive
network in normal kidney of the mouse,30 though these
c
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Figure 7 | Assessment of cell migration in Tk461, 173, and 188 human cortical renal fibroblasts. Whereas in controls, only a relative few
cells were able to migrate through the (a) artificial interstitial space, stimulation with 20 ng/ml CX3C-L resulted in an robust increase in
migration rate in the two fibroblast cell lines as well as in (b) primary cortical fibroblasts. Original magnification  200. (c) Mean values7s.d. of
six different experiments. *Po0.01 compared with negative controls. **Po0.01 compared to stimulation with 20 ng/ml CX3C-L. a-CX3C-R,
pre-incubation of fibroblasts with blocking anti-CX3C-R antibody.
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findings have not been confirmed in humans. Our knowledge
of human renal dendritic cells is still limited due to technical
difficulties in detecting and isolating these cells.33 In our
analysis, we found a group of interstitial cells colabeling for
the dendritic cell markers, CD11c and CX3C-R, suggesting
analogy to data obtained in mouse kidneys.30 Gro¨ne et al.12
described CX3C-R-positive cells within the stroma of medulla
and cortex in developing human kidneys, which could not be
colabeled by a series of antibody reagents directed against
monocyte/macrophage antigens (CD68, MAC387, MRP8,
and MRP14), or the stem cell antigen (CD34). This is not the
first study which described a CX3C-R expression in
mesenchymal cells, since the receptor has been detected in
synovial fibroblasts,10,34 in vascular smooth muscle cells7,32
and recently in mesenchymal stem cells in the brain.35 As
there is no specific antibody available for the detection of
human renal fibroblasts in vivo,3 we ascertained CX3C-R
expression by double immunofluorescence staining using the
myofibroblast marker a-smooth muscle actin or the me-
senchymal marker vimentin, respectively, in vivo and,
additionally, in well-characterized human fibroblast cell lines
Tk173 and Tk188 as well as in primary cortical fibroblasts
Tk461 in vitro.36
In progressive renal disease, there is an orchestra of several
mediators involved in the stimulation process. They can
roughly be divided into proinflammatory and profibrotic
cytokines.3,4 Additionally, recent studies emphasized the role
of chronic hypoxia with generation of reactive oxygen species
in the tubulointerstitium as a final common pathway to end-
stage renal failure.37 To elucidate whether proinflammatory
and/or fibrotic cytokines are involved in upregulation of
CX3C-R, we stimulated renal fibroblasts with the cytokines
tumor necrosis factor-a, IL-1b, PDGF, epithelial growth
factor, FGF-2, TGF-b, or H2O2 as a mediator of oxidative
stress. Neither proinflammatory nor profibrotic cytokines
lead to a significant change of CX3C-R expression, although
in microglia cells, TGF-b has been identified as a possible
inductor of CX3C-R in the rat.
31 However, H2O2 resulted in a
strong upregulation of CX3C-R expression, suggesting free
radicals as the main inductor of CX3C-R in human renal
fibroblasts. This effect was specific as we substantiated our
data by a dose-dependency and a complete abrogation after
co-incubation with H2O2 and the radical scavengers, NAC
and catalase. Moreover, these results concur with previous
studies which have shown an upregulation of CX3C-R in
activated microglial cells of the ischemic tissue 24 and 48 h
after ischemia,38 and a CX3C-R expression in vascular smooth
muscle cells in human atherosclerotic plaques.7 Interestingly,
very recent data by Furuichi et al.27 have shown a central role
of CX3C-L/CX3C-R in the ischemia–reperfusion injury model
of mouse kidneys concurring with our findings. With regard
to temporal aspects of pathogenesis, they found that CX3C-R-
dependent fibrosis was not an early, but a late event.
To ascertain a functional role of CX3C-R expression on
human renal fibroblasts, we chose their migration capacity as
a read-out system. Not unexpected, migration rate of these
fibroblasts was significantly upregulated by CX3C-L used as a
chemotactic stimulus. This effect was specific, since pre-
incubation of fibroblasts with CX3C-R-blocking antibody
partially abrogated migration and in concordance with a
previous study which has shown that CX3C-R-expressing
vascular smooth muscle cells undergo chemotaxis to CX3C-L.
7
In summary, expression of CX3C-R in human renal
fibroblasts may originate mainly from an upregulation by
reactive oxygen species. The exact role of this expression in
the course of interstitial fibrosis remains to be determined.
However, it may stimulate migration of fibroblasts toward
CX3C-L-expressing areas though that has not been proven in
our study. Further studies will determine additional func-
tional aspects of increased CX3C-R expression.
MATERIALS AND METHODS
Materials
The following cytokines and chemokines were purchased as
indicated: recombinant human IL-1b, tumor necrosis factor-a,
PDGF, epithelial growth factor, FGF-2, and TGF-b1 were purchased
from R&D Systems (Minneapolis, MN, USA). H2O2 was from
Boehringer Mannheim (Mannheim, Germany).
Primary antibodies: mouse monoclonal antibody to human
CD68 (Dako Diagnostika, Hamburg, Germany), CD11c (Invitrogen,
Karlsruhe, Germany), cytokeratin (which reacts with keratins 5, 6, 8,
and 17; Dako Diagnostika), vimentin (Boehringer Mannheim), and
a-smooth muscle actin (Paeselþ Lorei, Wiesbaden, Germany);
rabbit polyclonal antibody to CD3 (Dako Diagnostika); goat
polyclonal antibody to CX3C-R (Chemicon, Temecula, CA, USA);
rat polyclonal antibody to ZO-1 (Chemicon).
Secondary antibodies: anti-rabbit IgG-AP and anti-sheep/
goat IgG-AP, Fab fragments (both from Boehringer Mannheim),
rabbit anti-mouse-fluorescein-5-isothiocyanate, rabbit anti-mouse-
Rhodamin, rabbit anti-goat-phycoerythrin, goat anti-rat-fluorescein-5-
isothiocyanate, and peroxidase-conjugated goat anti-rabbit (all five
Dianova, Hamburg, Germany), horseradish peroxidase-conjugated
rabbit anti-mouse and rabbit anti-goat, horseradish peroxidase-
conjugated Envision anti-mouses or anti-rabbits (all four Dako
Diagnostika), rat anti-mouse-fluorescein-5-isothiocyanate (Invitrogen).
Trypsin ethylenediamine tetraacetic acid, Dulbecco’s modified
Eagle’s medium, Iscove’s modified Eagle’s medium, and fetal calf
serum were obtained from Gibco Ltd. (Paisley, Scotland). NAC and
catalase were obtained from Sigma (St Louis, MO, USA). Cell
culture dishes were from Becton Dickinson (Franklin Lakes, NJ,
USA). Peroxidase substrate, 3-amino-9-ethyl-carbazol, was pur-
chased from Dako Diagnostika.
Cell culture
Human renal fibroblast cell lines Tk173 (normal kidney derived)
and Tk188 (from a kidney with tubulointerstitial fibrosis) have been
described previously.36,39 Primary cortical Tk461 fibroblasts were
isolated from a biopsy of a 25-year-old female with IgA nephritis
and tubulointerstitial fibrosis involving 30% of the interstitium. The
cells were characterized and cultured as described previously.36,39
Immunohistochemical staining for CX3C-R, CD3, and CD68
Tissue samples from kidneys with a variable degree of interstitial
scarring of more than 40%, but a lack or only minor infiltrative
signs from biopsies with primary and secondary nephropathies
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(n¼ 24) were investigated by immunohistochemistry and fluores-
cence. Biopsies from normal areas uninvolved by neoplasia from
tumor nephrectomies (n¼ 8) were used as control kidneys. Tissue
specimens were fixed in 4% paraformaldehyde and used for
immunohistochemical detection as described below. The use of
human tissue samples has been approved by the Local Ethics
Committee (reference no #11/10/04).
CX3C-R, CD3, and CD68 were detected in paraformaldehyde
fixed, paraffin embedded tissue using a modified sandwich
technique as described previously.40,41 One micrometer thick
sections were put onto glass slides and dried at 371C overnight.
Specimens were deparaffinized in xylene, rehydrated in ethanol, and
distilled water and washed in phosphate-buffered saline (PBS).
Endogenous peroxidase activity was quenched for 15 min with 0.3%
H2O2 in methanol (vol/vol) at room temperature followed by
washing in PBS. Subsequently, specimens were microwave-heated
for 14 min in a buffer solution containing 1.8 mM citric acid and
8.2 mM sodium citrate followed by another washing in PBS. To
reduce non-specific binding, all slides were incubated for 30 min
with pooled, heat-inactivated anti-nuclear antibody, and anti-
neutrophil cytoplasmic antibody-negative tested human serum
diluted 1:5 in PBS. Thereafter, diluted primary antibodies (poly-
clonal goat antibody to human CX3C-R, polyclonal rabbit antibody
to CD3, or mouse monoclonal antibody to CD68), or goat/rabbit/
mouse IgG as a negative control were applied for 1 h at room
temperature. After washing in PBS, slides were incubated for 30 min
with a horseradish peroxidase-conjugated secondary rabbit anti-
goat antibody at a dilution of 1:50 (CX3C-R), Dako Envision anti-
rabbits (CD3) or Dako Envision anti-mouses (CD68). After
washing in PBS, a horseradish peroxidase-conjugated goat anti-
rabbit antibody at a dilution of 1:50 was applied for 30 min at room
temperature (only for CX3C-R). After one washing step in PBS,
slides were incubated with the chromogenic substrate 3-amino-9-
ethyl-carbazole for 5 min at room temperature to obtain positive
(red) tissue staining. The reaction was stopped by washing in PBS
followed by nuclear counter staining with hematoxylin. Slides were
mounted on glycerol-gelatin, and viewed by two-masked investiga-
tors using a non-inverted microscope.
Evaluation of sections
The degree of interstitial fibrosis was determined by morphometric
analysis after trichrome staining.42 The number of positively stained
interstitial cells of immunohistochemical staining for CX3C-R were
examined in consecutive sections of biopsies and compared with the
mean number of interstitial CD3- and CD68-positive cells of four
different visual fields at a magnification of  400. A raster ocular
with 10 10 fields was used at a magnification of  400. The mean
numbers of CX3C-Rþ and SCD3þ /CD68þ positively stained
cells are indicated as mean7s.d. of positive cells in fibrotic kidneys
is shown in the Figure 2. These data were collected in 24 fibrotic
kidneys. Additionally, for CX3C-R, the intensity, distribution, and
the number of different renal compartments, interstitium, endothe-
lial cells, tubular epithelial cells, epithelial cells of Bowman’s capsule,
and infiltrating leukocytes, were evaluated separately and scored (0
to þ þ þ ) as described previously.40
Single and double immunofluorescence staining of CX3C-R
and cytokeratine, ZO-1, vimentin, a-smooth muscle actin or
CD11c, respectively
Paraffin sections were double stained for CX3C-R and the
myofibroblast marker a-smooth muscle actin, the mesenchymal
marker vimentin, the epithelial cell markers ZO-1 and cytokeratine,
or the dendritic cell marker CD11c. The double labelings were
performed as described previously.43 Briefly, sections of 4–6 mm were
cut, air-dried overnight, and deparaffinized. Unspecific binding was
blocked by incubation with goat serum. Anti-CX3C-R antibody was
added in a concentration of 1:20. After incubation for 60 min and
several washes in PBS, labeling of a-smooth muscle actin, vimentin,
ZO-1, cytokeratine, or CD11c, respectively, was achieved by staining
with specific antibodies in a concentration of 1:50 to 1:200.
Subsequently, after additional incubation for 60 min and washing
procedures, fluorescein-5-isothiocyanate-anti-rabbit/goat/rat/mouse
and the appropriate rhodamin-labeled antibody were added
sequentially at a concentration of 1:20. After another several wash-
ings, nuclear counterstaining was performed by 40,6-diamidino-
2-phenylindole (1:50) for 2 min, before slides were mounted.
Pictures were taken either by double or by sequential exposure
using Zeiss camera and software (MC 200 Chip). Negative controls
consisted in substitution of the primary antibody with an irrelevant
rabbit polyclonal antibody. Positivity was evaluated with an
Axiophot S100 microscope (Zeiss, Jena, Germany).
Single immunfluorescence staining of CX3C-R in cultured renal
fibroblasts (Tk461, 173, and 188) were grown on two-well chamber
slides, fixed in acetone at 201C for 20 min. Except for double
labeling, the same staining protocol was used as described above.
Quantitative real-time PCR from kidney biopsies
The tubulointerstitial mRNA expression of CX3C-R was examined
after the microdissection of kidney biopsy specimens from patients
with tubulointerstitial fibrosis (fibrosis; n¼ 11) using quantitative
real-time PCR and biopsy material from the European Renal cDNA
Bank-Kroener Fresenius Biopsiebank (ERCB-KFB). Cadaveric,
donor kidneys with a lack of inflammatory or fibrotic changes
(control; n¼ 9) and non-fibrotic, non-inflammatory biopsy speci-
mens dedicated to variable primary or secondary nephropathies (no
fibrosis; n¼ 9) served as controls. After biopsy, the acquired kidney
tissue was processed and stored according to the protocol used in
the ERCB-KFB.44 Moreover, the acquired data were correlated with
clinical parameters (serum creatinine and proteinuria). The use of
kidney biopsies for research purposes was approved by the Local
Ethics Committee of the University of Goettingen, and written
consent was obtained from all patients before the biopsy.
RNA isolation and real-time PCR
Total RNA from cell culture experiments was extracted according to
a modification of the single step method of Chomczynski and
Sacchi45 with the phenol-guanidine isothiocyanate reagent RNA-Bee
(Tel-Test, Friendswood, TX, USA). Oligo dT-primed reverse
transcription was performed at 421C for 50 min after denaturation
of the RNA at 701C for 10 min. CX3C-R and GAPDH PCR of
reverse-transcribed RNA (3 mg) was performed using the primer set
indicated in Table 2. Real-time PCR was performed using a
Stratagene Mx3000P with reagents as dedicated (all Stratagene, La
Jolla, CA, USA) as follows: the reaction mixture consisted of 12.5 ml
of real-time PCR Master Mix and 0.25 ml of each primer (100 nM),
0.375 ml Rox dye solution and 1 ml probe solution, and the final
volume of the mixture was adjusted to 25 ml with the addition of
DNase- and RNase-free H2O. Amplification was started at 951C for
30 s as the first step, followed by 40 cycles of PCRs: at 951C for 30 s,
at 621C for 60 s, and at 721C for 30 s, successively. The final product
was extended and finalized at 951C for 60 s, 621C for 30 s, and 951C
for 30 s.
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Cell motility assay
Cell motility was assessed by a migration assay as described
previously.46 Briefly, in the lower chamber CX3C-L as chemotactic
agent was added to Iscove’s medium and wells were covered with
type I collagen-coated pyrovinyl-pyrrolidone-free polycarbonate
membrane with 8 mm pores (Neuro Probes Inc., Gaithersburg,
MD, USA). In the upper chamber, 5 103 cells/well (Tk461, 173, or
188) were added in Iscove’s modified Eagle’s medium, which were in
part pre-incubated for 1 h at 371C with CX3C-R blocking antibody
(1:200). The Boyden chamber was incubated for 4 h at 371C to allow
possible migration of cells through the membrane to the
lower chamber. Non-migrated cells were scraped off and nuclear
staining was performed with 40,6-diamidino-2-phenylindole accord-
ing to the manufacturer’s recommendations. Migrated cells
were counted per visual field using non-inverted microscopy
at magnification of  200. All experiments were repeated at least
six times.
Statistical analysis
Values are shown as mean7s.d. Statistical analysis was carried out as
indicated in the text using Statistica program Version 7.1 (StatSoft,
Tulsa, OK, USA). Results with levels of Po0.05 were considered
significant.
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